Insulin, blood glucose levels, and ischemic brain damage

Area of Science:

• Neuroscience
• Pharmacology
• Endocrinology

Background:

• Ischemic brain damage is a significant clinical challenge.
• Developing effective pharmacologic therapies is crucial for neuroprotection.
• Insulin is an accessible medication with potential neuroprotective properties.

Purpose of the Study:

• To evaluate the neuroprotective potential of insulin in preclinical models of global and focal ischemia.
• To elucidate the mechanisms underlying insulin's neuroprotective effects.
• To assess the clinical relevance of insulin for treating ischemic stroke and cardiac arrest encephalopathy.

Main Methods:

• Utilized animal models to simulate global and focal cerebral ischemia.
• Investigated insulin's effects on brain damage.
• Examined the roles of direct brain interaction and peripheral glucose reduction in insulin's neuroprotection.
• Assessed the involvement of insulin-like growth factor-1 receptors in direct mechanisms.

Main Results:

• Insulin demonstrated neuroprotective effects in both global and focal ischemia models.
• Two mechanisms were identified: direct brain interaction (partly via IGF-1 receptors) and indirect peripheral glucose reduction.
• Direct effects predominated in global ischemia.
• In focal ischemia, the effect was mainly via peripheral hypoglycemia, as neuroprotection was reduced by glucose co-administration.

Conclusions:

• Insulin exhibits neuroprotective capabilities in preclinical models of ischemic brain injury.
• Understanding the dual mechanisms of action is key to optimizing its therapeutic use.
• Clinical trials are warranted to investigate insulin's efficacy in human conditions like stroke and cardiac arrest encephalopathy, given its established safety profile.